Molecular insights into early malignant transition of hepatocellular carcinoma
Early liver cancers often rely on copy-number changes rather than mutations, with some showing inflamed immune profiles that might respond to newer immunotherapy approaches.
This multi-institutional study comprehensively profiled 21 very early hepatocellular carcinomas arising within 17 cancer-prone dysplastic nodules, revealing that copy number alterations (not point mutations) are the dominant driver of malignant transition. Notably, 43% of early HCCs displayed an inflamed but immune-evasive phenotype, opening a potential therapeutic window for early immunotherapy intervention.
What the study was
- Study design
- Genomic/molecular profiling study (multi-institutional cohort)
- Population
- Patients with very early HCC (veHCC) arising within dysplastic nodules (DNs)
- Sample size
- 21 very early HCCs within 17 cancer-prone dysplastic nodules
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Cancer Cell
Why it surfaced
Published in Cancer Cell; first comprehensive multi-institutional profiling of HCC premalignant-to-malignant transition; identifies two evolutionary scenarios (CNA-dominant vs inflamed immune-evasive) with direct early detection and immunotherapy implications; novel molecular insights not previously characterized at this resolution.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.